PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma

Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression.

Source: European Journal of Cancer - December 11, 2023 Category: Cancer & Oncology Authors: Eva Elleb æk, Shawez Khan, Lars Bastholt, Henrik Schmidt, Charlotte Aaquist Haslund, Marco Donia, Inge Marie Svane Source Type: research